Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Clinical trial NCT06300424 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06300424
- Sponsor
- Guangdong Provincial People's Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-01
- Primary completion
- 2026-01-26
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.